Madlen Jentzsch
Leipzig, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications
Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.
Journal: Experimental hematology & oncology
Published: June 21, 2026
Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.
Journal: Haematologica
Published: May 14, 2026
Low muscle quality, but not muscle mass, in abdominal CT-scans associates with adverse outcomes in AML patients undergoing an allogeneic stem cell transplantation.
Journal: Bone marrow transplantation
Published: April 11, 2026
Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients.
Journal: Bone marrow transplantation
Published: March 20, 2026
Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.
Journal: Journal of hematology & oncology
Published: March 15, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.
Journal: Bone marrow transplantation
Published: February 19, 2026
We included a total of 87 patients who received CAR T-cell therapy: 54 with none/mild chronic kidney disease (CKD) and 33 with moderate/severe CKD.
Journal: Transplantation and cellular therapy
Published: February 10, 2026
Clinician and medical scientists in internal medicine: hematology and oncology
Journal: Innere Medizin (Heidelberg, Germany)
Published: January 30, 2026
Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Journal: Haematologica
Published: December 23, 2025
Associations between CT Radiomics Analyses and Hematopoietic Cell Mobilization in Patients with Multiple Myeloma: An Exploratory Analysis.
Journal: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
Published: October 07, 2025
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.
Journal: HemaSphere
Published: September 11, 2025
Last Updated: 09/26/2026